GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » EPS without NRI

Cue Biopharma (Cue Biopharma) EPS without NRI : $-1.11 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma EPS without NRI?

Cue Biopharma's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.29. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.11.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 10.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cue Biopharma's EPS without NRI or its related term are showing as below:

CUE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -175.3   Med: -4.05   Max: 10.8
Current: 10.8

During the past 9 years, Cue Biopharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 10.80% per year. The lowest was -175.30% per year. And the median was -4.05% per year.

CUE's 3-Year EPS without NRI Growth Rate is ranked better than
56.88% of 1301 companies
in the Biotechnology industry
Industry Median: 5.1 vs CUE: 10.80

Cue Biopharma's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.11.

Cue Biopharma's EPS (Basic) for the three months ended in Dec. 2023 was $-0.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.11.


Cue Biopharma EPS without NRI Historical Data

The historical data trend for Cue Biopharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma EPS without NRI Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -1.66 -1.56 -1.41 -1.50 -1.11

Cue Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.38 -0.29 -0.29 -0.24 -0.29

Competitive Comparison of Cue Biopharma's EPS without NRI

For the Biotechnology subindustry, Cue Biopharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's PE Ratio without NRI falls into.



Cue Biopharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma  (NAS:CUE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cue Biopharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma (Cue Biopharma) Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director